Bortezomib was first licensed as an IV infusion, but it was later proven that the efficacy and safety were the same when it was given subcutaneously. Multiple myeloma (MM) is being increasingly recognized as a chronic disease, so improving quality of life is important – reducing time in hospital for IV administration of bortezomib would aid in this. Here, Tanya Burton, University Hospital of Wales, Cardiff, UK, explains how their team tested a self-administration programme with bortezomib in MM. She explains the aims, methods, results and next steps for this exciting development. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.